Germ-line mutations in the BRCA1 tumorsuppressor gene are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 contains a carboxylterminal domain (BRCT) that is shared with several other proteins involved in maintaining genome integrity. In an effort to understand the function of BRCA1, we sought to isolate proteins that interact with the BRCT domain. Purified BRCT polypeptide was used as a probe to screen a human placenta cDNA expression library by Far Western analysis. Here we report that BRCA1 interacts in vivo and in vitro with the Rb-binding proteins, RbAp46 and RbAp48, as well as with Rb. Moreover, the BRCT domain associates with the histone deacetylases HDAC1 and HDAC2. These results demonstrate that BRCA1 interacts with components of the histone deacetylase complex, and therefore may explain the involvement of BRCA1 in multiple processes such as transcription, DNA repair, and recombination.
More than half of families with inherited breast and ovarian cancer susceptibility are thought to harbor germ-line mutations in the BRCA1 gene. Frequent loss of the wild-type allele in tumors of mutation carriers suggests that BRCA1 acts as a tumor-suppressor gene. Surprisingly, mutations in BRCA1 in sporadic breast and ovarian cancer are extremely rare (1) (2) (3) . To date, more than 600 different mutations in the BRCA1 gene have been reported (Breast Cancer Information Core: www. nhgri.nih.gov͞Intramuralresearch͞Labtransfer͞Bic͞). The majority of these are truncation mutations distributed over the entire length of the gene. Several missense mutations have also been shown to segregate with cancer susceptibility (1, 4, 5) .
The BRCA1 gene was isolated and mapped to human chromosome 17q21 (6) . The gene encodes an 1,863-aa protein with an apparent molecular mass of 220 kDa. Only a few conserved sequence motifs have been identified in the BRCA1 protein: an amino-terminal RING finger, a carboxyl-terminal region that contains two repeats of a newly identified motif, designated BRCT (BRCA1 carboxyl terminus) domain (7) , and three nuclear localization signals in the central portion of the molecule (8) . However, much of the biochemical function of BRCA1 is unknown.
BRCA1 is found in nuclear foci that form in a cell cycledependent manner (9, 10) . Several lines of evidence suggest that BRCA1 expression is cell cycle regulated and plays a role in cell cycle checkpoints. BRCA1 mRNA is highly expressed during embryonic development and is increased in breast epithelia during pregnancy and in adult testis during the final stages of meiosis and spermatogenesis (11, 12) , suggesting a role in terminal differentiation. Brca1Ϫ͞Ϫ mouse embryos die early in development from cell proliferation defects, including cell cycle arrest (13, 14) . In human cell lines, BRCA1 expression suppresses cell growth (15) (16) (17) . The presence of the BRCT motif in BRCA1 also links it to cell cycle control. Many other cell cycle checkpoint proteins, such as the p53-binding protein (53BP1), fission yeast replication checkpoint proteins, (RAD9 and RAD4), the DNA repair proteins XRCC1 and XRCC4, and all members of the retinoblastoma protein family (Rbp107 and Rbp130) contain a BRCT motif (7, 18) .
A number of observations also link BRCA1 to transcription regulation. The carboxyl-terminal region has an intrinsic transactivation activity in cells when fused to the GAL4 DNAbinding domain (19, 20) . BRCA1 activates transcription of the cell cycle regulators p21 WAF͞CIP and MDM2 when cotransfected with p53 (21, 22) , supporting a role in the control of the cell cycle and proliferation. Other evidence suggests that BRCA1 plays a role in DNA repair. BRCA1 colocalizes with the double-strand break-repair, homologous recombination protein, RAD51, the human homolog of Escherichia coli RecA (9, 10, 23, 24) . After exposure to ionizing radiation and other DNA-damaging agents, BRCA1 becomes hyperphosphorylated, disperses from nuclear foci, and accumulates in proliferating cell nuclear antigen-containing structures (10) . Recently, it was reported that embryonic stem cells lacking BRCA1 are hypersensitive to ionizing radiation and are unable to mediate transcription-coupled repair after DNA damage (25) .
Several proteins are reported to bind and interact directly with BRCA1. Among them are components of the nuclear import pathway (8) that bind to the nuclear localization signals; a component of the ubiquitin pathway (26) ; and a novel RING finger͞BRCT domain-containing protein, BARD1 (27) , binding to the RING finger motif. Recently, p53, RNA helicase A, and CtIP were reported to bind BRCA1, supporting its role in transcriptional regulation (21, 22, (28) (29) (30) .
We hypothesized that the carboxyl terminus of BRCA1, harboring a trans-activation function and consisting of two BRCT domains, would interact with other proteins that mediate tumor suppression, transcription regulation and, DNA repair. We screened a human placental cDNA expression library by a Far Western method (31) to identify proteins that interact with the carboxyl terminus of BRCA1. We found that the retinoblastoma-binding protein, RbAp46, interacts in vitro with the BRCT domain as well as with full-length BRCA1 in vivo. RbAp46, together with its homolog RbAp48, were first isolated based on interaction with the carboxyl terminus of the retinoblastoma protein, Rb (32) (33) (34) . These proteins, members of the WD (Trp-Asp) repeat family, are highly similar in sequence and are functionally related (34) . Recently, RbAp48 was found to be one of the three subunits of chromatin assembly factor 1 (35, 36) . Both RbAp46 and RbAp48 are components of histone deacetylase complexes and are involved in chromatin remodeling (37, 38) . Additionally, we found that the carboxyl terminus of BRCA1 associates with the histone deacetylases HDAC1 and HDAC2, implying that BRCA1 is a component of a histone deacetylase complex.
Glutathione S-transferase (GST) Fusion Proteins and GST Pull-Down Experiments. GST and GST fusion proteins were expressed in E. coli DH5␣ (GIBCO͞BRL) or TOP10 (Invitrogen) cells transformed with pGEX4T, pGST-BRCT, pGST-NH 2 -BRCA1, pGSTp46-BD, pGSTp46-FL, pGSTp48, pGTRb, pGT-Rb⌬Ex21, or pGT-Rb⌬Ex22. GST fusion proteins were purified by affinity chromatography with glutathioneSepharose (Amersham Pharmacia) beads as described (40) , and protein concentration was estimated on a Coomassie-blue stained SDS͞PAGE gel. Purified pGST-HD (huntingtin) was a gift of H. Reddy (National Human Genome Research Institute). Approximately equal amounts of different GST fusion proteins were mixed with 35 S-labeled proteins synthesized by an in vitro reticulocyte coupled transcription͞ translation system TNT (Promega) according to manufacturer's instructions and diluted in binding buffer (50 mM Tris⅐HCl, pH7.5͞150 mM NaCl͞1 mM EDTA͞0.3 mM DTT͞ 0.1% Nonidet P-40͞0.5 mM PMSF͞1 g͞ml leupeptin͞2 g͞ml aprotinin and pepstatin). Beads were extensively washed 3-5 times with wash buffer (50 mM Tris⅐HCl, pH7.5͞ 150 mM NaCl͞1 mM EDTA͞0.3 mM DTT͞0.5% Nonidet P-40 and mixture of protease inhibitors as described above). Bound proteins were separated on SDS͞10% PAGE and visualized by using autoradiography.
Protein Extract Preparation and Coimmunoprecipitation. Nuclear extracts were prepared from subconfluent HeLa cells for coimmunoprecipitation as described (41), with some modifications. Briefly, cells were harvested and washed twice with ice-cold PBS and once with buffer A [20 mM Hepes, pH 7.9͞1.5 mM MgCl 2 ͞10 mM KCl͞0.5 mM DTT͞0.1 mM EDTA͞0.1 mM EGTA supplemented with mixture of protease inhibitors and phosphatase inhibitors (NaVO3, NaPPi, NaF)]. Cell pellets were incubated with buffer A on ice with for 15 min and then Dounce homogenized with 30-40 strokes. Samples were centrifuged, and pellets were resuspended in buffer C (20 mM Hepes, pH 7.9͞420 mM NaCl͞1.5 mM MgCl 2 ͞0.2 mM EDTA͞25% glycerol supplemented with protease and phosphatase inhibitors) for 15 min on ice. The samples were sonicated and centrifuged in an microcentrifuge at 16,000 ϫ g rpm for 15 min. Protein concentrations were determined by using the BCA protein assay (Pierce), and aliquots of nuclear extracts were stored at Ϫ80°C.
For coimmunoprecipitation, HeLa extracts (1.5 mg) diluted in binding buffer (supplemented with protease and phosphatase inhibitors) were incubated with the following mAbs: AB-3 against BRCA1 (Oncogene Science); RBBP against RbAp proteins (Transduction Laboratories, Lexington, KY); RbAp48-3-255 against RbAp (GeneTex, San Antonio, TX); or KM-1 against c-Jun (Santa Cruz Biotechnology) in the presence of protein A͞G Plus (Santa Cruz Biotechnology) overnight at 4°C on a rotator. The immune complexes were washed five times in wash buffer and loaded onto SDS͞6% PAGE. After electrophoresis, proteins were transferred to nitrocellulose membranes. Blots were blocked with 5% nonfat dry milk in TBST and incubated with 2 g͞ml mAb Ab-1 antibody against BRCA1 (Oncogene Science), or 1 g͞ml rabbit polyclonal antibody Ab-D (PharMingen). Proteins were visualized with horseradish peroxidase-conjugated secondary antibody and chemiluminescence (Pierce).
Whole-cell extracts from MCF-7 and HeLa cells were prepared for GST in vivo binding assays. Cells were harvested in RIPA buffer (0.15 mM NaCl͞0.05 mM Tris⅐HCl, pH 7.2͞1% Triton X-100͞1% sodium deoxycholate͞0.1% SDS, supplemented with protease and phosphatase inhibitors). Cellular debris was cleared by using centrifugation, and protein concentration was determined by the BCA protein assay (Pierce). For in vivo associations, approximately equal amounts of GST fusion proteins coupled to beads were incubated with 300 g of MCF-7 and HeLa whole-cell extracts diluted in binding buffer for 3 hr at 4°C on a rotator. Beads were extensively washed in washing buffer and bound proteins were separated on SDS͞10% PAGE, transferred into nitrocellulose membrane, and followed by Western blot analysis with goat polyclonal antibodies directed against HDAC1 and HDAC2 (Santa Cruz Biotechnology, and alkaline phosphatase detection.
Immunof luorescence Staining. HeLa cells or Saos2 cells grown in chamber slides to subconfluency were fixed for 30 min in 3% paraformaldehyde in PBS, and then rendered permeable with 0.1% Triton X-100 in PBS. Cells were washed with PBS, blocked with 10% goat serum in PBS, and then stained with 1:100 rabbit polyclonal antibody to BRCA1 (I-20, Santa Cruz Biotechnology), 1:100 mouse mAb to BRCA1 (Ab-1, Oncogene Science), 1:100 mouse mAb to RbAps (RBBP, Transduction Laboratories, Lexington, KY or 3-255, GeneTex, San Antonio, TX), 1:100 mouse mAb IF8 (Santa Cruz Biotechnology) to Rb or in combinations in humidified chamber for 30 min at 37°C. BRCA1, RbAps, and Rb were visualized with 1:200 anti-rabbit IgG conjugated to Texas red (Kirkegaard & Perry Laboratories) and 1:200 anti-mouse IgG conjugated to Alexa 488 (Molecular Probes), respectively. Immunofluorescence was recorded by using microscope and charge-coupled device camera.
RESULTS
Screening for Interacting Proteins. To identify proteins that collaborate with BRCA1 in mediating tumor suppression, we sought to isolate proteins that physically interact with BRCA1. The intrinsic transcriptional activity of the BRCT domain precluded the use of the yeast two-hybrid system. Therefore, a Far Western assay was developed using histidine-tagged BRCT fusion protein as a probe to screen a human placenta cDNA expression library (Fig. 1A) . A histidine-tagged CBF␤-SMMHC fusion protein was used as a negative control to eliminate clones that bound to the histidine tag. The sequence of one of the positive clones was identical to a portion (nucleotides 959-1,584) of the retinoblastoma-binding protein, RbAp46 (GenBank accession no. U35143). This clone, RY22, has a 1.0-kb insert and encodes 202 aa of the carboxyl terminus between amino acids 223 and 425 of RbAp46 followed by the 3Ј-untranslated region. Given the potential role of RbAp46 in chromatin remodeling, histone modifications, and gene expression, we further characterized this interaction between the BRCT domain of BRCA1 and RbAp46.
The BRCT Domain Interacts with RbAp46 and RbAp48 in Vitro. We tested whether the BRCT domain interacts in vitro with the RbAp46 carboxyl terminus, as identified by the library screen (designated BD), as well as with the full-length RbAp46 protein (FL). Purified GST proteins fused to either the RbAp46-BD or RbAp46-FL cDNA were incubated with in vitro-transcribed and -translated BRCT domain. Both GSTRbAp46-BD and GST-RbAp46-FL bound 35 S-labeled BRCT, whereas GST alone and GST-HD did not (Fig. 1B) . These results demonstrate that RbAp46 specifically binds the carboxyl terminus of BRCA1. Furthermore, these results indicate that the carboxyl terminus of RbAp46 between amino acids 223 and 425 is sufficient to bind the carboxyl terminus of BRCA1.
Because RbAp48 is 90% identical to RbAp46 at the amino acid level and is functionally related (34), we tested whether RbAp48 also interacts with 35 S-labeled BRCT. Results shown in Fig. 1B confirm that RbAp48 binds specifically to the carboxyl terminus of BRCA1.
Several mutations in the BRCT domain segregate with inherited breast cancer in families. We investigated the effect of two BRCT mutations (Fig. 1C) on in vitro binding to RbAp46. The mutation Y1853X is a nonsense mutation that introduces a stop codon 10 aa before the native stop codon. M1775R is a missense mutation found in several unrelated breast cancer families (1, 5) . Results shown in Fig. 1D show that the truncation mutation, Y1853X, has dramatically reduced binding to RbAp46 compared with wild-type BRCT, and the missense mutation M1775R does not bind at all. These results suggest that interaction with RbAp46 is important for BRCA1 function.
BRCA1 Associates with Rb-Binding Proteins in Vivo. To determine whether BRCA1 and the retinoblastoma-binding proteins can interact and form a complex in vivo, we performed coimmunoprecipitation assays. Immunoprecipitation of the endogenous Rb-binding proteins from extracts of HeLa cells by two different mAbs (RBBP, Transduction Laboratories, Lexington, KY; RbAp48-15G12, GeneTex, San Antonio, TX) revealed that BRCA1 coprecipitates with Rb-binding proteins but not with c-jun ( Fig. 2A; ref. 42) . Similar results were observed with MCF-7 cells (data not shown). To further (Fig. 3A) . These results define the region of RbAp46 between amino acids 223 and 425 as sufficient to interact with Rb, and suggest that sequences other than exons 21 and 22 in the carboxyl fragment of Rb pocket region are important for binding RbAp46 and BRCT. Comparable results were observed with full-length RbAp46 (data not shown). We then tested whether BRCA1 and Rb are part of a complex in vivo. Two-color immunostaining of Rb and BRCA1 with a rabbit polyclonal antibody against BRCA1 (I-20) and a mouse mAb against Rb (IF8, Santa Cruz Biotechnology), revealed BRCA1 and Rb colocalized in nuclear dots in HeLa cells (Fig. 3B) but not in Saos2 cells that contain a mutated Rb (data not shown). Taken together, these results suggest that BRCA1 and Rb interact in vivo; however, the interaction between RbAps and BRCA1 is independent of Rb.
BRCA1 Is a Component of Histone Deacetylases. Because RbAp46 and RbAp48 are components of histone deacetylase complexes, we investigated whether BRCA1 associates with other components of this complex. HeLa and MCF-7 whole- 
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Cell Biology: Yarden and Brody Proc. Natl. Acad. Sci. USA 96 (1999) cell extracts were incubated with GST alone, GST-BRCT, or GST-NH 2 BRCA1 (amino acids 1-304). Bound proteins were probed with antibodies for HDAC1 and HDAC2, the catalytic subunits of the histone deacetylase complex. Results shown in Fig. 4 indicate that BRCA1 associates with HDAC1 and HDAC2 via the BRCT domain either directly or indirectly in both cell lines. This interaction is specific, because GST alone or GST fused to the amino terminus of BRCA1 failed to bind HDAC1 and HDAC2.
DISCUSSION
We present evidence that BRCA1, via its carboxyl terminus, interacts with components of the complex containing human histone deacetylases HDAC1 and͞or HDAC2. We also demonstrate that BRCA1 directly interacts with Rb-binding proteins RbAp46 and RbAp48 as shown by in vivo associations and in vitro binding assays. Additionally, Rb binds to the BRCT domain of BRCA1, suggesting that these proteins may form a complex.
The association of BRCA1 with RbAp46 depends on the carboxyl terminus of RbAp46 and the BRCT domain in the carboxyl terminus of BRCA1. This region contains two BRCT motifs also found in other proteins involved in cell cycle checkpoints (7) . Two mutations in the second BRCT repeat associated with an elevated breast cancer risk, Y1853X and M1775R, disrupted the binding of BRCT to RbAp46, suggesting that the interaction between BRCA1 and RbAps is important for BRCA1 function. Moreover, these mutations interfere with the transcriptional activity of BRCA1 and reverse the BRCA1-mediated growth suppression in yeast (19, 20, 39) . Of interest, Rb contains a diverged version of the BRCT consensus (18) , raising the possibility that Rb-binding proteins may interact with other BRCT-containing proteins as well.
Recent evidence demonstrates that RbAp46 and RbAp48 are components of histone deacetylase complexes (37, 38) . RbAp48 is also a component of the chromatin assembly factor, CAF-1 (35, 36) , and RbAp46 has recently been identified as a component of human acetyltransferase HAT1 activity (43) . Thus, both RbAp46 and RbAp48 may serve as targeting molecules whose function is to bring HDAC, HAT1, or CAF-1 enzymes, to their histone substrates. Our results further support the notion that BRCA1 is involved in processes that require chromatin remodeling, such as DNA repair or recombination, in addition to transcription regulation. Association of the BRCT domain of BRCA1 with Rb suggests not only that both proteins may exist in a complex, but also that BRCA1 and Rb may act in concert. In light of recent reports that Rb acts through histone deacetylases to repress transcription (44) (45) (46) , our results point to a potential mechanism by which Rb and BRCA1 mediate tumor suppression. It would be of interest to examine the role of BRCA1 in regulation of transcription from E2F-repressed promoters. The association of BRCT with Rb does not involve exon 21 and exon 22 of the ''pocket region'' of Rb because these Rb mutants still bind the BRCT domain. Similarly, RbAp46 does not bind to these sequences in the pocket region of Rb. As HDAC was reported to interact with the pocket region (44, 46) , it is likely that BRCA1 and RbAps will occupy distinct binding sites on Rb and can potentially form a multiprotein complex.
Changes in chromatin structure have been shown to be important in modulating the activity of multiprotein complexes responsible for transcription, replication, recombination, and DNA repair (47) (48) (49) (50) (51) . Histone acetylation is generally associated with gene activation. Many transcriptional coactivators such as p300͞CBP, pCAF, and SRC-1 possess intrinsic histone acetyltransferase activity (reviewed in refs. 52 and 53). Recently, BRCA2 has been shown to have acetyltransferase activity (54) . Histone deacetylases are often associated with nucleosomal condensation and transcriptional repression (55, 56) .
To date, BRCA1 has been reported to activate transcription of the cell cycle regulator p21 waf͞cip , thought in part to mediate the cell cycle arrest effect of BRCA1 when ectopically expressed (16) . BRCA1-mediated activation of specific genes could occur by the sequestration of histone deacetylases from DNA promoters. Such a mechanism has been suggested for the E1A carboxyl-terminal domain, which activates transcription by disrupting a promoter bound complex of CtBP (E1A carboxyl terminus binding protein) and HDAC1 (57) .
Conversely, BRCA1 may potentially repress transcription of genes that promote cell proliferation. Dual action of both inducing and repressing gene expression has been described for other tumor-suppressor genes. Rb represses transcription of E2F-dependent promoters involved in DNA metabolism, such as TK and DHFR genes, and activates expression of terminal differentiation markers such as NF-IL6 and BRG1. p53 activates gene expression of proteins involved in cell cycle arrest such as p21 waf͞cip and MDM, whereas repressing transcription from enhancers and promoters of DNA viruses. Therefore, the possibility that the association of BRCA1 with histone deacetylase directly represses transcription of a subset of genes involved in growth cannot be excluded. Finally, BRCA1 has been implicated in DNA repair (9, 10, 25) . Given that DNA repair requires chromatin remodeling before and after removal of lesions, association of BRCA1 with multiprotein complex-involved chromatin dynamics could contribute to the execution of these processes.
